CD63 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1068707	0.53	7/20
SCHEMBL2476093	1.00	6/20
SCHEMBL2481321	0.67	6/20
SCHEMBL2479630	0.62	6/20
SCHEMBL2478652	0.61	6/20
SCHEMBL2475942	0.60	6/20
SCHEMBL2479524	0.48	6/20
SCHEMBL2482740	0.74	5/20
SCHEMBL3787189	0.60	5/20
SCHEMBL2481186	0.55	5/20
SCHEMBL2893233	0.53	5/20
SCHEMBL2894330	0.53	5/20
SCHEMBL2480849	0.50	5/20
SCHEMBL2898374	0.49	5/20
SCHEMBL2897884	0.48	5/20
SCHEMBL1069035	0.46	5/20
SCHEMBL2481130	0.46	5/20
SCHEMBL2543802	0.74	4/20
SCHEMBL2483012	0.60	4/20
SCHEMBL2483763	0.57	4/20

Clinical trials — most relevant to CD63 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2	PHASE4	COMPLETED
Basophil Activation Test (BAT) Sensitivity in Child Food Allergy	PHASE4	COMPLETED
The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa	PHASE2/PHASE3	UNKNOWN
Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM)	PHASE2/PHASE3	UNKNOWN
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	PHASE2/PHASE3	COMPLETED
Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery	PHASE1/PHASE2	UNKNOWN
Safety of Injection of Placental Mesenchymal Stem Cell Derived Exosomes for Treatment of Resistant Perianal Fistula in Crohn's Patients	PHASE1/PHASE2	UNKNOWN
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia	PHASE1/PHASE2	RECRUITING
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors	PHASE2	UNKNOWN
Identification of New Diagnostic Protein Markers for Colorectal Cancer	nan	COMPLETED
The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients	nan	RECRUITING
Extracellular Vesicle Surface Markers In Acute Cerebrovascular Syndromes.	nan	UNKNOWN
JAK2V617F Mutated Endothelium Has a Stem Cell Potential in Primary Myelofibrosis: a New Disease Ontogenesis for Chronic Myeloproliferative Disorders	nan	COMPLETED
Characterization of Extracellular Vesicles in Breast Cancer Patients	nan	RECRUITING
Immunophenotyping and Xist Gene in AML	nan	UNKNOWN
Expanded Access to Zofin for Patients With COVID-19	nan	AVAILABLE
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit	nan	UNKNOWN
Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors	nan	RECRUITING
CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis	nan	COMPLETED
Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer	nan	RECRUITING
The Role of Circulating Soluble CD74 in Acute Lung Injury	nan	COMPLETED
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis	nan	UNKNOWN
Clinical and Surgical Outcomes of Total Thyroidectomy in Basedow's Disease: the Effect of Lugol Solution	nan	UNKNOWN
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study	nan	COMPLETED
When the Kidney Reacts to Nutritional Changes	nan	COMPLETED
Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)	nan	NOT_YET_RECRUITING
Predictors of Positive Food Challenge	nan	UNKNOWN
CD133 Expression in Mammary Invasive Ductal Carcinoma	nan	UNKNOWN
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CD63 binder may also engage these)

Protein	Name	Similarity
Q9XSK2	—	0.999	Q9XSK2 →
P41731	—	0.998	P41731 →
Q28709	—	0.998	Q28709 →
Q76B49	—	0.995	Q76B49 →
P28648	—	0.994	P28648 →
Q6AYR9	—	0.987	Q6AYR9 →
O60635	—	0.985	O60635 →
Q4R7W6	—	0.984	Q4R7W6 →
Q8R3G9	—	0.982	Q8R3G9 →
Q99J59	—	0.981	Q99J59 →
Q3T0S3	—	0.980	Q3T0S3 →
P19075	—	0.980	P19075 →
Q62283	—	0.980	Q62283 →
P40237	—	0.979	P40237 →
P19331	—	0.978	P19331 →
P41732	—	0.978	P41732 →
Q5RC27	—	0.978	Q5RC27 →
Q6NWG0	—	0.978	Q6NWG0 →
Q7YQL0	—	0.977	Q7YQL0 →
Q61451	—	0.977	Q61451 →
Q7YQK9	—	0.977	Q7YQK9 →
Q26499	—	0.976	Q26499 →
O70401	—	0.976	O70401 →
CD81	CD81 antigen	0.976	landscape →
Q2KIS9	—	0.976	Q2KIS9 →
Q5RAS5	—	0.975	Q5RAS5 →
P35762	—	0.974	P35762 →
Q58DM3	—	0.974	Q58DM3 →
P62079	—	0.974	P62079 →
Q62745	—	0.973	Q62745 →